MedTrace Logo

A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

NCT04813354 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2023-05-15

Study results available
· View outcomes & findings →

Summary

This study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER DPIs, by comparing the incidence of critical and overall errors, participant preference, willingness to continue with the inhaler and time to correct use. ELLIPTA® is a registered trademark of GlaxoSmithKline (GSK) and BREEZHALER® is a registered trademark of Novartis.

Conditions

Interventions

DEVICE

ELLIPTA

* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1 * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2 * BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1 * BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

DEVICE

BREEZHALER

* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1 * ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2 * BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1 * BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-14
Primary Completion
2021-07-08
Completion
2021-07-08

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04813354 on ClinicalTrials.gov